高氡暴露地区人群中代谢酶GSTM1基因多态性与肺癌易感性关系的研究

A CASE-CONTROL STUDY OF ASSOCIATION BETWEEN GENETIC POLYMORPHISMS OF METABOLIZING ENZYMES GSTM1 AND LUNG CANCER SUSCEPTIBILITY FOR THE PEOPLE LIVING IN HIGH RADON-EXPOSED AREA

本文采用病例-对照研究方法,以多重聚合酶链反应扩增技术,对高氡暴露地区53例肺癌患者和72例对照人员进行了代谢酶GSTM1基因多态性检测,并分析了不同人群中该基因多态性与肺癌发病风险的关系,以探讨高氡暴露地区人群中GSTM1基因多态性与肺癌易感性的关系。结果表明,GSTM1基因功能型和缺陷型在肺癌组分布分别是38.9%、64.1%,在对照组分布分别为43.1%、56.9%。GSTM1基因缺陷型的肺癌发病风险为1.35倍(95%可信限0.652～2.81),有效剂量<50mSv的人群中GSTM1基因缺陷型的肺癌发病风险是功能型的1.14倍(95%可信限0.198～6.60)。从以上结果可以看出,GSTM1基因功能型在肺癌组的分布频率低于对照组的分布频率,而缺陷型在肺癌组的分布频率高于对照组的分布频率;GSTM1基因缺陷型使肺癌的发病风险有增高的趋势,但未见显著性差异。

A case-control study was performed with 53 lung cancer patients and 72 frequency-matched controls to assess the role of genetic polymorphisms of metabolizing enzymes Glutathione S-transferases M1 （ GSTM1 ） in risk of developing lung cancer for the people living in high radon-exposed area. The associations between genotypes and risk of developing lung cancer were estimated by odds ratios （ORs） and their 95% confidence intervals （CIs） calculated by unconditional logistic regression. The frequencies of GSTM 1 positive polymorphism and null polymorphism were 38.9% and 64.1% respectively in lung cancer patients. The frequencies of GSTM1 positive polymorphism and null polymorphism were 43.1% and 56.9% respectively in controls. The risk of developing lung cancer for GSTM1 null polymorphism was 1.35-fold （95%CI0.652 -2.81 ）. GSTM1 null polymorphism with effective dose 〈50 mSv could increase the risk of developing lung cancer （ OR 1.14, 95% CI 0. 198 -6.60）. The frequency of GSTM1 positive polymorphism of lung cancer patients was lower than that of the controls. Based on those data, the frequency of GSTM1 null polymorphism of lung cancer patients was higher than that of the controls. There was an association between genetic polymorphism of GSTM1 and lung cancer. But the differences were not all statistically significant.